# Evolva

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evolva

- Industry: Biotechnology
- Headquarters: Reinach, Switzerland
- Website: www.evolva.com
- Total disclosed funding: $71M
- Latest round: Series B (Dec 11, 2009)
- Investors on record: 14

## About

Based in Switzerland, Evolva Holding SA is engaged in developing and commercializing innovative natural ingredients for diverse industries, with a focus on sustainability and biosynthetic solutions.Evolva Holding SA is focused on the creation of natural ingredients, founded in 2004 in Reinach, Switzerland. The company was involved in 15 funding deals, with its most recent transaction being a Trade Sale to Lallemand Inc. for CHF 20 million on December 28, 2023. Following this acquisition, Evolva AG will be delisted from the SIX Swiss Exchange. The company's leadership includes CEOs Christian Wichert and Matija Tomaskovic.Evolva Holding SA specializes in the development and commercialization of innovative natural ingredients across various sectors, particularly in food, beverages, and health. The company’s main products comprise biosynthetic flavors and fragrances, which enhance the sensory appeal of food and beverages while emphasizing sustainable practices. Evolva serves a wide range of markets, including North America, Europe, and Asia, catering to food manufacturers, beverage companies, and personal care brands, and aims to fulfill the growing consumer demand for clean-label products focused on health and environmental responsibility.In the most recent year 2023, Evolva reported a revenue of CHF 4,629,128.90, with an EBITDA of CHF -111,362,139.30.Following the recent acquisition by Lallemand Inc., Evolva Holding SA aims to leverage the funds from the CHF 20 million deal to enhance its product offerings and expand into additional markets. The company will focus on launching new biosynthetic ingredients and increasing its presence in North America and Europe. The management anticipates that the strategic integration with Lallemand will facilitate further growth opportunities and market expansion.

## Funding rounds

- Series B, Dec 11, 2009, $16M — Auriga Partners, Wellington Partners, Novartis Venture Fund, BioMed Partners, Dansk Erhvervsinvestering, Renaissance Foundation & Management, Entrepreneurs Fund Management
- Series B, Oct 22, 2009, $27M — Auriga Partners, Wellington Partners, Aravis, Novartis Venture Fund, BioMed Partners, Astellas Venture Management, Dansk Erhvervsinvestering, Renaissance Foundation & Management, Heartcore Capital
- Series A, Dec 1, 2006, $9.8M — Aravis, Novartis Venture Fund, Astellas Venture Management, SEED Capital, Ventureast, Vaekstfonden
- Series A, Mar 21, 2005, $2.5M — Ventureast
- Series A, Aug 16, 2004, $15M — Aravis, Novartis Venture Fund, Astellas Venture Management, Dansk Erhvervsinvestering, Symbion Capital, Vaekstfonden

## Investors

- Aravis (https://capitalatlas.ai/funds/aravis) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A, Series B
- Dansk Erhvervsinvestering (https://capitalatlas.ai/funds/dansk-erhvervsinvestering) — Series A, Series B
- Symbion Capital (https://capitalatlas.ai/funds/symbion-capital) — Series A
- Vaekstfonden (https://capitalatlas.ai/funds/vaekstfonden) — Series A
- Ventureast (https://capitalatlas.ai/funds/ventureast) — Series A
- SEED Capital (https://capitalatlas.ai/funds/seed-capital) — Series A
- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series B
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series B
- Renaissance Foundation & Management (https://capitalatlas.ai/funds/renaissance-foundation-management) — Series B
- Heartcore Capital (https://capitalatlas.ai/funds/heartcore-capital) — Series B
- Entrepreneurs Fund Management (https://capitalatlas.ai/funds/entrepreneurs-fund-management) — Series B